Linfoma de Hodgkin: características anátomo-clínicas e análise de novo biomarcador (IMP3)

• Ano de defesa: 2015
• Autor(a) principal: Moraes, Marcelo Padovani de Toledo [UNESP]
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Estadual Paulista (Unesp)
• Palavras-chave em Português: Hodgkin, Doença de; Linfoma; Prognostico; Revisão; Marcadores bioquímicos; Hodgkin's disease; Biochemical markers
• Link de acesso: http://hdl.handle.net/11449/132038; http://www.athena.biblioteca.unesp.br/exlibris/bd/cathedra/05-10-2015/000849806.pdf

Hodgkin lymphoma (HL) is a hematopoietic neoplasm that characteristically affects young adults and, if untreated, presents a fatal clinical course. Early and accurate diagnosis of this lymphoma associated with modern therapeutic management, on the other hand, has promoted a dramatic decrease in mortality rates. Despite this, around 15-20% of patients show unsatisfactory progression, with resistance to primary therapy or early relapse following treatment. The literature comprises numerous studies attempting to determine prognostic profiles that are capable of selecting candidate patients for specific therapies. Insulin-like growth factor mRNA binding protein 3 (IMP3) has been described as a biomarker that indicates worse prognosis in several malignancies, particularly carcinomas; however, studies of IMP3 in hematopoietic malignancies are rare. To assess their potential prognostic role in HL, IMP3 expression was studied in 61 cases and included stratification of immunostaining intensities (0, +, ++ and +++) and their relation to status of life, clinical data and morphological and immunohistochemical features. Intense IMP3 expression (+++) was observed in 61% (34/56) cases and showed a strong indication of association with better disease-free survival. Our findings show that IMP3 is a potential biomarker of better prognosis in HL